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Despite the use of Bacillus Calmette-Gu´ erin (BCG) vaccination for many years, infants and young children exposed to adults with
infectious forms of tuberculosis (TB) are at high risk of developing complicated TB disease. This risk is much higher amongHIV-
infected children, and data on BCG protective eﬃcacy in HIV-infected children is lacking. Recent research on BCG safety in HIV-
infected infants has resulted in policy shifts, but implementation is challenging. New approaches to preventing TB among infants
and children, particularly HIV-infected infants, are needed. This paper brieﬂy reviews BCG safety and eﬃcacy considerations in
HIV-infected infants and discusses other approaches to preventing TB, including new TB vaccines and vaccination strategies.
1.Introduction
It is estimated that worldwide over 100 million doses of
BCG vaccine are administered per year [1]. However, the
exact nature of protection against TB disease following BCG
vaccination has not been fully elucidated. Vaccine eﬃcacy
and safety in the context of HIV infection is controversial
and is a topic of considerable recent and ongoing research.
Such research is highly relevant to global public health as
TB endemic areas frequently overlap with areas of high HIV
prevalence, and HIV/TB coinfection is common amongst
both adults and children. Between 2004 and 2006, the
incidence of TB in HIV-infected infants in Cape Town,
South Africa was reported as 1596 per 100000 compared to
66 per 100000 in HIV-uninfected infants [2]. Infants and
young children exposed to adults with TB are at high risk
for developing severe and complicated forms of TB disease.
Diagnostic diﬃculties and complexity related to the clinical
management of coinfectedinfants and children contributeto
the scale of the paediatric problem. There is an urgent need
for safe and eﬀective TB prevention strategies in infants and
children, particularly those who are HIV-infected.
2.BCGEfﬁcacy
The clinical eﬃcacy of a vaccine is measured in terms of
the percentage of reduction in disease among vaccinated
individuals that is attributable to vaccination. Eﬃcacy repre-
sents a composite outcome of three events: (1) the propor-
tion of vaccine “take”, (2) the degree of vaccine protection,
and (3) the duration of protective immunity [3].
Research on BCG eﬃcacy has been hampered by the
failuretoidentifyareliableclinicalorimmunologicalparam-
eter that indicates protection against the development of TB
disease following BCG vaccination. Neither the presence of
a BCG scar nor tuberculin skin test reactivity correlates with
protection against TB [4].
In an attempt to better understand BCG-induced immu-
nity, investigators have described the nature of immune
responses following BCG vaccination and latent TB infec-
tion. In many individuals, BCG vaccination is capable of
inducing a polyfunctional T cell response dominated by cells
capable of producing type 1 cytokines (including interferon-
(IFN-) gamma, interleukin- (IL-) 2 and tumour necrosis
factor (TNF)) [5].
There have also been attempts to delineate speciﬁc
immune defects in individuals who are highly susceptible
to developing TB disease or complications following vac-
cination with live, attenuated BCG, including HIV-infected
individuals and infants with primary immunodeﬁciency
disorders [3]. Among HIV-infected infants not receiving
antiretroviral therapy, BCG has been shown to induce a
much lower frequency and quality of speciﬁc CD4 T cells
than in HIV-uninfected infants, and this persists throughout2 Tuberculosis Research and Treatment
the ﬁrst year of life [6]. Six-week-old HIV-exposed (born
to HIV-infected mothers) but uninfected infants who had
received BCG at birth had lower IFN-gamma responses
than HIV-unexposed infants [7]. In children receiving
antiretroviral therapy, antimycobacterial immune responses
may be restored [8]. Individuals with genetic disorders of the
IFN-gamma cytokine pathway are particularly predisposed
to developing active TB disease [9].
Large randomized clinical trials have provided data on
BCG eﬃcacy. In the HIV-uninfected infants, administration
ofasingledoseofBacillusCalmette-Gu´ erin(BCG)vaccineat
or soon after birth has been shown to aﬀord approximately
80% protection against disseminated forms of TB (miliary
TB and TB meningitis) in infancy [10–12]. BCG is less
eﬀective and variable in preventing pulmonary TB in infants
and adults with eﬃcacies between 0% and 80% reported in
clinical trials during the last century [12]. These ﬁndings
suggest that BCG is unlikely to be eﬀective in preventing
infection with M. tuberculosis but may prevent progression
of infection to disease, particularly disseminated forms of
TB disease. Since disseminated disease is more common
amongst young children and is associated with high morbid-
ityandmortality,BCGvaccinationofnewborns may becost-
eﬀective as a paediatric intervention but has little impact on
transmission of TB amongst adults [3]. Factors believed to
inﬂuence the variable protection include BCG strain vari-
ation, vaccine dose, patient age at vaccination, nutritional
status,hostgeneticfactors, environmentalmycobacterialand
helminthic infections, and geographic location [13–15].
Data on the protective eﬃcacy of BCG amongst HIV-
infected individuals is very limited, as most large BCG
eﬃcacy studies were done prior to the onset of the HIV pan-
demic.InHIV-infectedadults,BCGvaccinationhasnotbeen
shown to have a statistically signiﬁcant eﬀect in preventing
pulmonary or disseminated TB disease [16]. A few studies
have been reported in children. A Zambian retrospective
case-control study reported no protective eﬀect of BCG in
116 TB cases and 154 controls without TB; by contrast,
a 59% protective eﬀect (OR 0.41, 95% CI 0.18–0.92) of
BCGvaccinationwasfoundinHIV-uninfectedchildren[17].
Another retrospective study in Argentina found that BCG-
vaccinated HIV-infected children did not have a signiﬁcantly
lower incidence of TB compared to unvaccinated children
during a 12-year followup period (Abstract WeOa0104,third
IAS Conference on HIV Pathogenesis and Treatment, 2005,
[18]).
Such retrospective epidemiological studies are limited by
potential bias due to nonstandardised criteria for the diag-
nosis of TB, potential selective BCG vaccination practices,
and poor documentation of BCG vaccination or the use of
a BCG scar to indicate BCG vaccination which has been
reported to be less frequent in HIV-infected compared to
HIV-uninfected children [19].
The prospect of prospective randomized trials evaluating
the safety and eﬃcacy of BCG vaccination in HIV-exposed
and HIV-infected infants and children is complicated by
the factors described: lack of a clinical or immune correlate
of BCG-induced protection, evidence of eﬃcacy against
disseminated forms of TB in HIV-uninfected children,
diﬃculties in diagnostic criteria for TB disease in children,
and the fact that the HIV status of infants is not known
at birth which is when BCG vaccine is administered in
developing countries. An additional area of uncertainty is
the eﬀect of early initiation of antiretroviral therapy (ART)
in infants on BCG-induced immunity, and the potential role
of delayed BCG vaccination until after ART or revaccination
approaches.
3.SafetyofBCG Vaccine
The normal evolution of the local skin reaction following
intradermal vaccinationwithBCGincludesthedevelopment
of an erythematous macule (3 weeks after vaccination),
formation of a papule (by 6 weeks), shallow ulcer (by 10
weeks), and healing (by 14 weeks).
Prior to the HIV pandemic, BCG had a good safety
record with mostly minor reactions reported and serious
adverse events generally restricted to infants with primary
immunodeﬁciency disorders including severe combined
immunodeﬁciency (SCID), chronic granulomatous disease
(CGD), DiGeorge syndrome, IFN-gamma receptor deﬁ-
ciency, and IL-12 deﬁciency [19]. Local adverse events in
infants have been estimated to occur in <0.04% of vaccine
recipients and disseminated BCG disease in <0.002% of
vaccine recipients [20, 21].
More serious BCG disease has been described in HIV-
infected infants and even in an adult HIV-infected individ-
ual,30years aftervaccination[22].Asubsequentmulticentre
study showed that the risk of disseminated BCG disease in
immunosuppressed HIV-infected adults who received BCG
vaccination during infancy was very low [23]. However, the
risk ofbothlocaland disseminated BCGdisease amongHIV-
infected infants and children has emerged as a signiﬁcant
public health concern.
Two sentinel studies from South Africa, although ret-
rospective case series, suggested a much higher prevalence
of culture-conﬁrmed distant or disseminated BCG disease
among immunosuppressed HIV-infected infants not yet
on ART than was previously recognized. The ﬁrst study
highlighted one important explanation for underrecognition
of BCG disease. Laboratory culture of respiratory secretions
(including gastric lavage samples) for tuberculosis identiﬁes
M. tuberculosis complex (which includes M. tuberculosis and
M. bovis strains amongst others), and further speciation
is not routinely performed. In this study, researchers per-
formed further speciation of the M. tuberculosis complex
in 183 cultured isolates from 49 HIV-infected children
diagnosed with “tuberculosis” [24]. Danish strain M. bovis
BCG was isolated from ﬁve infants all of whom were severely
immunosuppressed. Within the group of ﬁve infants, four
had axillary lymphadenitis ipsilateral tothe BCG vaccination
site, two had evidence of pulmonary BCG disease, and two
had regional and pulmonary BCG disease.
The second study was a hospital-based retrospective
review of culture-conﬁrmed BCG disease in children <13yrs
of age diagnosed over a three-year period [25]. Among
25 children, 88% had local disease, 32% had distant or
disseminated disease, and 20% had both. Seventeen ofTuberculosis Research and Treatment 3
the 25 children were HIV-infected, and two had other
immunodeﬁciencies. All eight children with distant or
disseminated disease were severely immunodeﬁcient (six
were HIV infected), and the mortality rate in this group was
75%.
Mathematical modeling approaches estimate the risk of
disseminated BCG in HIV-infected infants in the South
African context to be between 329 and 417 per 100000
vaccine recipients, assuming 95% BCG coverage,HIV preva-
lence of 12.4–15.4% pregnant women, and a vertical HIV
transmission rate of 5% [26]. This is extremely high.
Another important observation is that BCG is a rela-
tively common association with the immune reconstitution
inﬂammatory syndrome (IRIS) among infants and young
children initiating ART. IRIS refers to the occurrence of
a paradoxical infectious or inﬂammatory condition in a
patient recovering from severe immune deﬁciency [27].
The “unmasking” of TB following the initiation of ART is
o n eo ft h ec o m m o n e s tf o r m so fI R I Sd e s c r i b e di na d u l t s
whereas BCG-IRIS presenting as a “paradoxical” form of the
syndrome has been reported in 3–14.8% of children starting
ART in South African and Thai cohorts [28–30]. The usual
clinical manifestation of BCG-IRIS is with inﬂammatory
ipsilateralaxillary orregionallymphadenitis,with orwithout
inﬂammation or abscess formation at the vaccination site.
Younger age and higher baseline HIV viral load have been
identiﬁed as risk factors for the development of BCG-IRIS
[29]. Although suspected distant or disseminated disease,
particularly involving the lungs or bone, has been described
in the context of BCG-IRIS, it is unclear whether dissemi-
nation may occur early after vaccination at birth but only
manifest clinically following ART initiation at a few months
of age.
Should BCG vaccination at birth be delayed in HIV-
exposed infants and avoided altogether in HIV-infected
infants?
As discussed above, clinical and immunological evidence
for the protective eﬃcacy of BCG vaccination in HIV-
infected infants is lacking, and there are serious concerns
regarding the safety of BCG in HIV-infected infants both
before and after ARTinitiation. In 2007,the Global Advisory
Committee on Vaccine Safety (GACVS) of the World Health
Organization (WHO) published revised recommendations
contraindicating BCG vaccination in children with HIV
infection [31].
A more relevant consideration is whether BCG vaccine
should be given to all infants including infants born to
HIV-infected mothers at birth or whether selective deferral
of BCG vaccination should be instituted for HIV-exposed
infants until the HIV infection status is deﬁnitively estab-
lished by virological testing at around 6 weeks of age.
Increasing coverage of measures to reduce mother-to-child
transmission of HIV (including maternal and infant pre-
ventive antiretroviral medicines or maternal antiretroviral
therapy, and safe infant feeding) results in the majority
of infants born to HIV-infected mothers ultimately being
uninfected. These infants are expected to beneﬁt from BCG
vaccination without the risk of disseminated BCG disease
reported in HIV-infected infants. Delaying BCG vaccination
from birth to 10 weeks of age may result in an enhanced
memory CD4 T cell response including polyfunctional
T cells expressing IFN-γ,T N F - α, and IL-2 when measured
at 1 year of age in HIV-uninfected infants [32].This may also
be applicable to HIV-exposed uninfected infants, but further
laboratory and clinical studies are needed.
There is a concern that selective vaccination deferral
practices could threaten the beneﬁts of high BCG coverage
rates as a result of HIV-exposed but uninfected children
missing followup vaccination after 6 weeks of age. The
BCG Working Group of the Child Lung Health Section
of the International Union Against TB and Lung Disease
has published a consensus statement on relevant criteria
to be considered by HIV/TB programmes considering
introduction of selective BCG vaccination deferral [33].
These include high uptake of maternal HIV testing coupled
with eﬀective prevention of mother-to-child transmission
(PMTCT) strategies, including maternal ART; early viro-
logical diagnosis of HIV infection in infants coupled with
institution of ART;coordination of PMTCT, vaccination and
TB programmes to minimise loss to followup, implement
alternative TB preventive strategies, and deliver successful
vaccination following selective nonvaccination at birth.
Current implementation of selective vaccination strategies is
not feasible in most countries that are highly endemic for
HIV and TB, and universal BCG vaccination of infants is
likely to continue for some time to come.
4. Other Ways of ProtectingHIV-Infected
Infants against TB
Early initiation of ART (particularly before 12 weeks of age)
in HIV-infected infants regardless of clinical or CD4 count
criteria signiﬁcantly reducesmortality and TB incidence[34]
and may reduce the frequency and severity of BCG-IRIS,
probably as a result of immune preservation (Abstract 600,
fourteenth Conference on Retroviruses and Opportunistic
Infections, 2008, [35]).
Routine pre-exposure isoniazid prophylaxis for all HIV-
infected infants (<12 months of age) is not currently
recommended by WHO following the results of a double-
blind randomized placebo-controlled trial involving 452
infants that showed no beneﬁt (38, Abstract G2-1346a,
48th Interscience Conference on Antimicrobial Agents and
Chemotherapy 2008, [36]). A previously reported study
showed signiﬁcant reductions in mortality and incidence of
TB among HIV-infected infants and children receiving INH
prophylaxis [37]. The recent WHO guidelines recommend
six months of isoniazid preventive therapy (IPT) for HIV-
infected children of any age with exposure to an infectious
TB source case after exclusion of TB disease and six months
of IPT for HIV-infected children >12 months of age who are
not known to be exposed to TB [38].
Administration of BCG vaccine to HIV-infected infants
or young children after initiation of ART and attaining
some degree of immune reconstitution is another interesting
approach that has not yet been studied in any detail.
However, in view of the safety concerns with live vaccines
in general and BCG in particular among HIV-infected or4 Tuberculosis Research and Treatment
otherwise immunocompromised individuals and the revised
WHO recommendation to avoid BCG in HIV-exposed
infants, it seems unlikely that BCG will undergo prospective
evaluation in HIV-infected infants or children.
New BCG vaccines hold considerable promise in the
medium to longer term and may ultimately address the
questions surrounding eﬃcacy and safety in a sustainable
manner. Advances in genetic technology and sequencing
of the M. tuberculosis (M. tb) genome during the 1990s
have accelerated the development of new candidate TB
vaccines, and ﬁve have progressed to the stage of Phase
1 human trials. Since HIV-infected individuals carry such
a large proportion of the overall burden of TB disease,
an important characteristic of the ideal TB vaccine is
safety, immunogenicity, and eﬃcacy in preventing TB in
individuals with HIV infection or AIDS, including children.
Live attenuated mycobacterial vaccines, such as BCG, are
likely to be superseded by recombinant vectored vaccines or
subunit vaccines [39].
New vaccines need to be tested at diﬀerent phases of
the natural history of TB infection and disease develop-
ment.Vaccinationstrategiesincludepreinfectionvaccination
administered at or shortly after birth (as with BCG) or
as a booster following BCG at the time of birth. This
approach is well suited to high burden TB environments,
and the boosting approach has the advantage of potentially
improving the immunogenicity and eﬃcacy of BCG while
avoiding the ethical dilemma of avoiding BCG altogether.
The disadvantage of the boosting approach following BCG
is that the safety concerns with BCG use particularly in HIV-
infected infants remain.
Another approach is postinfection vaccination following
evidence of natural infection with M. tb with the aim of
enhancingorboostingimmunityandpreventingprogression
to TB disease. This approach, provided the vaccine is safe,
would be particularly relevant to HIV-infected individuals
including young children with their high rates of TB expo-
sure and infection, and increased risk of progression to TB
disease, including severe forms of extrapulmonary disease.
Two recombinant vectored vaccines (MVA85A and AERAS-
402) are being investigated for use as boosting vaccines in
BCG-primed individuals and for postinfection vaccination.
These are the most likely candidate vaccines and vaccination
strategies around which ethically acceptable clinical trials
among infants and children, including those who are HIV
exposed or HIV infected, could be designed [39].
Few, if any, of the leading candidate TB vaccines have
reached clinical studies in HIV-infected children as yet,
however, these two recombinant vectored vaccines have
made considerable progress along the vaccine development
pipeline. MVA85A consists of modiﬁed vaccinia Ankara
(MVA) genetically engineered to express M. tb antigen
85A [40]. MVA-based vaccines have a good safety record
following extensive use during the smallpox eradication
era and in candidate HIV vaccine studies [41, 42]. Safety
and immunogenicity data for MVA85A in HIV-infected,
TB-infected, and HIV-TB coinfected adults and in healthy
children and infants isawaited (HawkridgeA.in Proceedings
of Tuberculosis Vaccines for the World Conference, 2006, see
[43]). The AERAS-402vaccine uses a serotype 35 adenovirus
unable to replicate but modiﬁed to express a fusion protein
of three M. tb antigens (85A, 85B, and TB10.4). It was
developed to be used as a boosting vaccine in individuals
primed with BCG and has entered human clinical studies
[39].
A subunit vaccine, Mtb72F comprises a fusion protein
of two immunogenic M. tb proteins combined with an
adjuvant. A modiﬁcation, the M72 vaccine, was shown to be
safe and immunogenic in healthy adult volunteers, although
more reactogenic in individuals previously exposed to M. tb.
Clinical trials are ongoing in Europe and South Africa [39].
Challenges to the development of new TB vaccines
include the limited understanding of protective immune
responses against TB, diﬃculties in identifying latent infec-
tion and diﬀerentiating infection from disease, diﬃculty
in deﬁning clinical endpoints of trials, and the need for
improvedsurveillanceofTB-relatedmorbidityandmortality
in the context of large Phase 3 vaccine trials carried out over
many years [39].
Another signiﬁcant challenge relates to ethical issues
surrounding the introduction of a new TB vaccine in the
context of an existing though very imperfect vaccine (BCG)
which is routinely administered to all newborn infants in
TB endemic countries. It is likely that few if any countries
have successfully implemented the WHO recommendation
to avoid BCG vaccination in HIV-exposed newborn infants
until the deﬁnitive HIV status can be established at 6
weeks of age. From an ethical perspective, vaccine trials
involving infants and children that exclude BCG vaccination
in their design need to consider the inclusion of alternative
TB preventive measures, such as the provision of isoniazid
preventive therapy and routine early initiation of ART
for HIV-infected infants and children, as these are likely
to become standard-of-care interventions. Since new TB
vaccines directed at HIV-infected individuals are unlikely to
be live attenuated vaccines, IPT is unlikely to interfere with
measures of vaccine immunogenicity but may reduce the
risk of TB-infected individuals developing active TB disease.
Immune preservation or restoration due to ART, however,
is likely to increase vaccine immunogenicity as compared
to HIV-infected individuals not receiving ART. The moral
imperative to incorporate such interventions into vaccine
trials involving HIV-infected infants and children should
override other considerations.
5.Conclusion
BCG vaccination of HIV-infected infants is of uncertain
eﬃcacy and is associated with signiﬁcant safety concerns
in untreated infants and in those on ART. The diagnosis
and management of BCG disease is complex, leading to
underrecognition and suboptimal care in resource-limited
settings. Universal BCG immunization at birth is associated
with high rates of coverage whereas selective deferral of
BCG immunization until HIV infection status of infants is
established risks signiﬁcantly reduced BCG coverage rates
amongstthelargeproportionofHIV-exposedbutuninfected
infants. Universal early initiation of ART in HIV-infectedTuberculosis Research and Treatment 5
infants may currently be the most eﬀective approach to
reducing the risk of both BCG disease and TB disease in this
group. Isoniazid preventive therapy for TB-exposed infants
and older children is an important additional TB prevention
strategy while new BCG vaccines with better safety and
eﬃcacy proﬁles are under investigation.
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